Altimmune with ticker code (ALT) now have 7 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The target price ranges between 44 and 25 with a mean TP of 30.86. Now with the previous closing price of 16.4 this would indicate that there is a potential upside of 88.2%. The day 50 moving average is 13.49 and the 200 day MA is 13.12. The market cap for the company is $605m. Find out more information at: http://altimmune.com
Altimmune, a clinical stage biopharmaceutical company, focuses on developing intranasal vaccines, immune modulating therapies, and treatments for liver disease. The company develops AdCOVID, a single-dose intranasal vaccine that is in Phase I clinical trial to protect against COVID-19; T-COVID, an intranasal immune modulating therapeutic candidate, which is in Phase I/II clinical trial to evaluate the potential of T-COVID to prevent clinical worsening in patients with early COVID-19; NasoShield, an anthrax vaccine product candidate that is in a Phase 1b trial; and NasoVAX, a recombinant intranasal vaccine product candidate, which completed Phase IIa clinical trial for the treatment of seasonal and pandemic use. It also focuses on developing ALT-801, a novel peptide-based dual GLP-1/glucagon receptor agonist for the treatment of non-alcoholic steatohepatitis that is in Phase I clinical trial; and HepTcell, an immunotherapeutic product candidate, which is in Phase II clinical trial for patients chronically infected with the hepatitis B virus. Altimmune has a collaboration with the University of Alabama at Birmingham for the development of AdCOVID. The company is headquartered in Gaithersburg, Maryland.
You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.